AU2006299293B2 - Factor H for the treatment of chronic nephropathies and production thereof - Google Patents

Factor H for the treatment of chronic nephropathies and production thereof Download PDF

Info

Publication number
AU2006299293B2
AU2006299293B2 AU2006299293A AU2006299293A AU2006299293B2 AU 2006299293 B2 AU2006299293 B2 AU 2006299293B2 AU 2006299293 A AU2006299293 A AU 2006299293A AU 2006299293 A AU2006299293 A AU 2006299293A AU 2006299293 B2 AU2006299293 B2 AU 2006299293B2
Authority
AU
Australia
Prior art keywords
factor
patient
antibody
chronic nephropathy
independent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006299293A
Other languages
English (en)
Other versions
AU2006299293A1 (en
Inventor
Peter Gronski
Bernd Hoppe
Christoph Licht
Christine Skerka
Peter Zipfel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
CSL Behring GmbH Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland filed Critical CSL Behring GmbH Deutschland
Publication of AU2006299293A1 publication Critical patent/AU2006299293A1/en
Application granted granted Critical
Publication of AU2006299293B2 publication Critical patent/AU2006299293B2/en
Assigned to CSL BEHRING GMBH reassignment CSL BEHRING GMBH Request for Assignment Assignors: CSL BEHRING GMBH, INSTITUT FUR NATURSTOFF-FORSCHUNG E.V.-HKI, UNIVERSITAT ZU KOLN
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2006299293A 2005-09-19 2006-06-13 Factor H for the treatment of chronic nephropathies and production thereof Ceased AU2006299293B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05020409 2005-09-19
EP05020409.8 2005-09-19
PCT/EP2006/005631 WO2007038995A1 (en) 2005-09-19 2006-06-13 Factor h for the treatment of chronic nephropathies and production thereof

Publications (2)

Publication Number Publication Date
AU2006299293A1 AU2006299293A1 (en) 2007-04-12
AU2006299293B2 true AU2006299293B2 (en) 2011-08-18

Family

ID=36001069

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006299293A Ceased AU2006299293B2 (en) 2005-09-19 2006-06-13 Factor H for the treatment of chronic nephropathies and production thereof

Country Status (7)

Country Link
US (2) US20090118163A1 (enExample)
EP (1) EP1928483B1 (enExample)
JP (2) JP2009508822A (enExample)
KR (1) KR20080048034A (enExample)
AU (1) AU2006299293B2 (enExample)
CA (1) CA2627264A1 (enExample)
WO (1) WO2007038995A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2894145B1 (fr) * 2005-12-07 2008-10-17 Lab Francais Du Fractionnement Utilisation de facteur h du complement a titre de medicament
EP2129686B1 (en) * 2007-03-20 2016-07-13 CSL Behring GmbH Methods for industrial scale production of therapeutic complement factor h preparations from human plasma
AU2009313203B2 (en) * 2008-11-10 2015-08-27 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
GB0904427D0 (en) 2009-03-13 2009-04-29 Lachmann Peter Treatment of diseases related to hyperactivity of the complement system
WO2011011753A1 (en) * 2009-07-23 2011-01-27 Baxter International Inc. Manufacture of factor h (fh) and fh-derivatives from plasma
FR2952640B1 (fr) 2009-11-16 2012-12-07 Lab Francais Du Fractionnement Procede de fabrication d'une preparation de facteur h
FR2952539B1 (fr) 2009-11-16 2012-01-13 Lab Francais Du Fractionnement Preparation d'un concentre de facteur h
GB0922659D0 (en) 2009-12-24 2010-02-10 Univ Edinburgh Factor H
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
JP6092776B2 (ja) 2010-09-15 2017-03-08 セルデックス セラピューティクス インコーポレイテッド 可溶性補体受容体Ｉ型（ｓＣＲ１）を用いる慢性腎症の処置
RU2013121589A (ru) * 2010-10-13 2014-11-20 Октафарма Аг Способ очистки фактора комплемента н
FR2981661B1 (fr) * 2011-10-25 2015-06-19 Lfb Biotechnologies Procede de preparation du facteur h humain
FR2983212A1 (fr) 2011-11-28 2013-05-31 Lfb Biotechnologies Aptameres anti-fh, procede pour leur obtention et utilisations
AU2013203048A1 (en) 2013-03-15 2014-10-02 Baxalta GmbH Isolation of factor h from fraction i paste
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
US20150079613A1 (en) 2013-08-07 2015-03-19 Ryan Kitchel Atypical hemolytic uremic syndrome biomarker proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0222611A2 (en) * 1985-11-08 1987-05-20 Sankyo Company Limited Human complement factors and their therapeutic use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492325B1 (en) * 1998-05-22 2002-12-10 Boys Town National Research Hospital Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
FR2894145B1 (fr) 2005-12-07 2008-10-17 Lab Francais Du Fractionnement Utilisation de facteur h du complement a titre de medicament

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0222611A2 (en) * 1985-11-08 1987-05-20 Sankyo Company Limited Human complement factors and their therapeutic use

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
HOGASEN K. ET AL: JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 9, no. PROGRAM AND ABSTR. ISSUE, September 1997, pages 474A-475A, & 30TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF NEPHROLOGY; SAN ANTONIO, TEXAS, USA; NOVEMBER 2-5, 1997 *
HOGASEN K. ET AL: MOLECULAR IMMUNOLOGY, vol. 36, no. 4-5, March 1999, page 305, & 7TH EUROPEAN MEETING ON COMPLEMENT IN HUMAN DISEASE; HELSINKI, FINLAND; JUNE 17-20, 1999 *
HSU STEPHEN I-HONG ET AL:JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGYvol. 14, no. Supplement 2, July 2003, pages S186-S191, *
JANSEN J. H ET AL: "In situ complement activation in porcine membranoproliferative glomerulonephritis type II" KIDNEY INTERNATIONAL, vol. 53, no. 2, February 1998, pages 331-349, *
LICHT C ET AL., AMERICAN JOURNAL OF KIDNEY DISEASES 2005, vol. 45, no. 2, February 2005 (2005-02), pages 415-421, *
MHATRE A ET AL: "ISOLATION OF BOVINE COMPLEMENT FACTOR H" VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 14, no. 4,1987, pages 357-375, *
MOURE F ET AL: "Coupling process for plasma protein fractionation using ethanolprecipitation and ion exchange chromatography." MEAT SCIENCE, vol. 64, no. 4, August 2003, pages 391-398, *
TANG SYDNEY ET AL: "Role of complement in tubulointerstitial injury from proteinuria" KIDNEY AND BLOOD PRESSURE RESEARCH, vol. 25, no. 2, 2002, pages 120-126, *

Also Published As

Publication number Publication date
US20090118163A1 (en) 2009-05-07
WO2007038995A1 (en) 2007-04-12
JP2012184251A (ja) 2012-09-27
EP1928483B1 (en) 2016-12-28
JP2009508822A (ja) 2009-03-05
CA2627264A1 (en) 2007-04-12
AU2006299293A1 (en) 2007-04-12
KR20080048034A (ko) 2008-05-30
EP1928483A1 (en) 2008-06-11
US10137165B2 (en) 2018-11-27
US20110046062A1 (en) 2011-02-24

Similar Documents

Publication Publication Date Title
US10137165B2 (en) Factor H for the treatment of chronic nephropathies and production thereof
US6846649B1 (en) Recombinant human mannan-binding lectin
DK2814502T3 (en) Von Willebrand Factor variants with improved Factor VIII binding affinity
US9347051B2 (en) Coagulation factor X polypeptides with modified activation properties
AU2006254311B2 (en) Coagulation factor X polypeptides with modified activation properties
EP2796145B1 (en) A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
EP1816201A1 (en) Modified coagulation factor VIIa with extended half-life
AU2015283822B2 (en) Modified von willebrand factor
EP2007885B1 (en) Method of increasing the in vivo recovery of therapeutic polypeptides
JP2004180682A (ja) 改変第ＶＩＩＩ因子ｃＤＮＡおよびその誘導体
CN108779165B (zh) 突变的冯·维勒布兰德因子
US20150031621A1 (en) Method for purification of complement factor h
HK1203409B (en) A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: CSL BEHRING GMBH

Free format text: FORMER OWNER WAS: INSTITUT FUR NATURSTOFF-FORSCHUNG E.V.-HKI; CSL BEHRING GMBH; UNIVERSITAT ZU KOLN

MK14 Patent ceased section 143(a) (annual fees not paid) or expired